articleThe LancetAug 4, 2009Closed access

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

JLJeffrey L. LennoxEDEdwin DeJesusALAdriano LazzarinRBRichard B. PollardJVJosé Valdez Madruga

Emory University · Orlando Immunology Center · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

620
total citations
FWCI
39.30
Percentile
100%
References
49
Citations per year

Authors

16

Topics & keywords

Topics
Keywords
  • Raltegravir
  • Efavirenz
  • Medicine
  • Antiretroviral therapy
  • Human immunodeficiency virus (HIV)
  • Internal medicine
  • Double blind
  • Physical therapy
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding